Iron deficiency specialist Vifor Pharma, a part of Switzerland-based Galenica Group (SIX: GALN) has inked a deal with east coast, US biotech firm Akebia Therapeutics (Nasdaq: AKBA).
The deal relates to the American company's candidate vadadustat, which has completed Phase II trials for the treatment of anemia associated with chronic kidney disease.
The companies have agreed to sell vadadustat to Fresenius Medical Care (NYSE: FMS) dialysis clinics in the USA, pending regulatory approval and the inclusion of vadadustat in a bundled reimbursement model.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze